Payment overview · 2025
General Payments
$1,421.53
75 reported records · 15 companies
Healthcare provider profile · identity verified
Eric Phelan
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · ENDWELL, NY · NPI 1386192318
Verified facts
What the public records show
CMS Open Payments records show Eric Phelan received $1,421.53 in general payments during 2025 across 75 reported records.
ABBVIE INC. accounted for 20.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 33 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Eliquis, Farxiga, Jardiance, Ozempic, Rybelsus, Shingrix, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 135 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 246 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $284.01 | 20.0% | 18 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $252.99 | 17.8% | 9 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $240.18 | 16.9% | 16 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $164.67 | 11.6% | 8 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $99.61 | 7.0% | 5 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $63.15 | 4.4% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $62.05 | 4.4% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $57.06 | 4.0% | 3 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $54.53 | 3.8% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $47.22 | 3.3% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $34.95 | 2.5% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $15.95 | 1.1% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $15.83 | 1.1% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.94 | 1.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.39 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,421.53 | 75 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $206.56 | 14 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $163.20 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $155.26 | 11 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $143.59 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $87.91 | 4 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $76.76 | 4 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $70.51 | 4 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $63.15 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $62.13 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $58.38 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $57.45 | 3 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $54.53 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $47.22 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $41.23 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $40.86 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $40.86 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $40.17 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $38.54 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $37.45 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $34.95 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $24.60 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $20.00 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $20.00 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.55 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $16.20 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $16.20 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $16.20 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $15.95 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $15.83 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $14.94 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $14.41 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.39 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.39 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 135 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 246 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 43 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 53 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 28 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 22 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 88 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
40 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
43 | 15 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
135 | 135 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
22 | 18 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
88 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
53 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
28 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
246 | 72 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 790 | 239 |
| Amlodipine Besylate | Amlodipine Besylate | 489 | 151 |
| Omeprazole | Omeprazole | 481 | 145 |
| Levothyroxine Sodium | Levothyroxine Sodium | 428 | 118 |
| Losartan Potassium | Losartan Potassium | 384 | 105 |
| Tamsulosin Hcl | Tamsulosin Hcl | 356 | 109 |
| Metoprolol Succinate | Metoprolol Succinate | 337 | 113 |
| Lisinopril | Lisinopril | 280 | 87 |
| Simvastatin | Simvastatin | 260 | 78 |
| Metformin Hcl | Metformin Hcl | 259 | 89 |
| Eliquis | Apixaban | 246 | 72 |
| Pantoprazole Sodium | Pantoprazole Sodium | 231 | 75 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 213 | 78 |
| Hydrochlorothiazide | Hydrochlorothiazide | 203 | 63 |
| Furosemide | Furosemide | 199 | 64 |
| Meloxicam | Meloxicam | 185 | 55 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 183 | 40 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 171 | 55 |
| Finasteride | Finasteride | 156 | 50 |
| Sertraline Hcl | Sertraline Hcl | 145 | 52 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 135 | 135 |
| Gabapentin | Gabapentin | 133 | 46 |
| Zolpidem Tartrate | Zolpidem Tartrate | 132 | 22 |
| Metformin Hcl Er | Metformin Hcl | 125 | 42 |
| Allopurinol | Allopurinol | 122 | 36 |
| Famotidine | Famotidine | 121 | 33 |
| Fluticasone Propionate | Fluticasone Propionate | 119 | 53 |
| Carvedilol | Carvedilol | 118 | 33 |
| Clopidogrel | Clopidogrel Bisulfate | 116 | 41 |
| Montelukast Sodium | Montelukast Sodium | 113 | 38 |
| Trazodone Hcl | Trazodone Hcl | 112 | 36 |
| Metoprolol Tartrate | Metoprolol Tartrate | 102 | 31 |
| Alprazolam | Alprazolam | 101 | 27 |
| Celecoxib | Celecoxib | 91 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 89 | 27 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 88 | 24 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 88 | 22 |
| Baclofen | Baclofen | 87 | 26 |
| Tramadol Hcl | Tramadol Hcl | 87 | 24 |
| Lorazepam | Lorazepam | 83 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 83 | 29 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 81 | 25 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 78 | 25 |
| Valsartan | Valsartan | 73 | 24 |
| Glimepiride | Glimepiride | 71 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 71 | 22 |
| Glipizide Er | Glipizide | 70 | 20 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 70 | 15 |
| Irbesartan | Irbesartan | 67 | 20 |
| Spironolactone | Spironolactone | 65 | 20 |
| Potassium Chloride | Potassium Chloride | 63 | 20 |
| Benazepril Hcl | Benazepril Hcl | 62 | 18 |
| Meclizine Hcl | Meclizine Hcl | 61 | 32 |
| Prednisone | Prednisone | 59 | 40 |
| Xarelto | Rivaroxaban | 58 | 16 |
| Ezetimibe | Ezetimibe | 55 | 17 |
| Ramipril | Ramipril | 55 | 16 |
| Atenolol | Atenolol | 54 | 15 |
| Jardiance | Empagliflozin | 53 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 50 | 15 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 50 | 16 |
| Warfarin Sodium | Warfarin Sodium | 50 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 49 | 14 |
| Mirtazapine | Mirtazapine | 48 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 46 | 19 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 46 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 45 | 15 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 45 | 19 |
| Breo Ellipta | Fluticasone/Vilanterol | 44 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 44 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 43 | 35 |
| Farxiga | Dapagliflozin Propanediol | 43 | 15 |
| Clonazepam | Clonazepam | 42 | suppressed |
| Ketoconazole | Ketoconazole | 40 | 14 |
| Synthroid | Levothyroxine Sodium | 40 | 13 |
| Azithromycin | Azithromycin | 38 | 35 |
| Ondansetron Odt | Ondansetron | 37 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 37 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 36 | 11 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 35 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 34 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 33 | 11 |
| Clobetasol Propionate | Clobetasol Propionate | 32 | 14 |
| Diazepam | Diazepam | 31 | suppressed |
| Entresto | Sacubitril/Valsartan | 31 | 11 |
| Januvia | Sitagliptin Phosphate | 31 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 30 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 30 | 20 |
| Fenofibrate | Fenofibrate | 29 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 29 | suppressed |
| Mupirocin | Mupirocin | 29 | 16 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 28 | 28 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 28 | suppressed |
| Ozempic | Semaglutide | 28 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 28 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 27 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 27 | suppressed |
| Bupropion Xl | Bupropion Hcl | 26 | 12 |
| Estradiol | Estradiol | 26 | suppressed |
| Hydrocortisone | Hydrocortisone | 26 | 14 |
| Invokana | Canagliflozin | 26 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 25 | 14 |
| Topiramate | Topiramate | 25 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 24 | 12 |
| Levetiracetam | Levetiracetam | 23 | suppressed |
| Nystatin | Nystatin | 23 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 22 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 22 | 18 |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 21 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 21 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 21 | suppressed |
| Aripiprazole | Aripiprazole | 20 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 20 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 20 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 20 | suppressed |
| Rybelsus | Semaglutide | 20 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 19 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 19 | suppressed |
| Pregabalin | Pregabalin | 19 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 18 | suppressed |
| Cephalexin | Cephalexin | 18 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 17 |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 18 | suppressed |
| Torsemide | Torsemide | 18 | suppressed |
| Trulicity | Dulaglutide | 18 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 17 | suppressed |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 15 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 16 | suppressed |
| Oxycontin | Oxycodone Hcl | 16 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 14 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 14 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Xolair | Omalizumab | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Febuxostat | Febuxostat | 12 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Alprazolam Er | Alprazolam | 11 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Dexamethasone | Dexamethasone | 11 | 11 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,421.53 · 75 records | ABBVIE INC. | ABRYSVO, AIRSUPRA, AREXVY, Auvelity, BREZTRI, CAPLYTA, COMIRNATY, CREON, Cologuard Collection Kit, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, INJECTAFER, INSPIRE, JARDIANCE, LINZESS, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error